Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Japan, March 3, 2009 - Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter “Astellas”) today announced that Astellas has terminated the License...
Read more about Astellas Terminates Agreement on Antipsychotic Agent ASP2314/ACR-16
TOKYO, JAPAN and SANTA CLARA, CA- March 2, 2009 - Astellas Pharma Inc. (Astellas) and XenoPort, Inc. (NASDAQ: XNPT) today announced preliminary top-line results from a Phase 2 clinical trial of...
Tokyo, Japan, February 27, 2009 – Astellas US Holding, Inc., a wholly owned subsidiary of Astellas Pharma Inc., today announced that it has filed a lawsuit in the Delaware Chancery Court against...
Read more about ASTELLAS FILES LAWSUIT AGAINST CV THERAPEUTICS
Tokyo, Japan, February 27, 2009 – Astellas Pharma Inc. (“Astellas”) today announced that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced a cash tender offer for all...
Tokyo, Japan, February 23, 2009 – Astellas Pharma Inc. (“Astellas”) today commented on CV Therapeutics, Inc’s. (Nasdaq: CVTX) announcement that its Board of Directors has rejected...
Follow us
